ArticleFrontiers in medicine2021
Characteristics and Prognostic Factors of Pulmonary Fibrosis After COVID-19 Pneumonia.
Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- The RACOON viral pneumonia score for structured reporting of pre-existing, acute, and post-pneumonic findings on chest CT.Frontiers in medicine · 2025Article
- A predictive model for post-COVID-19 pulmonary parenchymal abnormalities based on dual-center data.Scientific reports · 2024Article
- Blood Eosinophils Matter in Post-COVID-19 Pneumonia.Diagnostics (Basel, Switzerland) · 2024Article
- Longitudinal analysis of the lung proteome reveals persistent repair months after mild to moderate COVID-19.Cell reports. Medicine · 2024Article
- Diverse roles of SARS-CoV-2 Spike and Nucleocapsid proteins in EndMT stimulation through the TGF-β-MRTF axis inhibited by aspirin.Cell communication and signaling : CCS · 2024Article
- Itaconate as a key regulator of respiratory disease.Clinical and experimental immunology · 2024Review
- Histone deacetylases: potential therapeutic targets for idiopathic pulmonary fibrosis.Frontiers in cell and developmental biology · 2024Review
- Chest CT features and functional correlates of COVID-19 at 3 months and 12 months follow-up.Clinical medicine (London, England) · 2023Article
- Review
- Pulmonary fibrosis: A short- or long-term sequelae of severe COVID-19?Chinese medical journal pulmonary and critical care medicine · 2023Review
- Post-COVID Interstitial Lung Disease-The Tip of the Iceberg.Immunology and allergy clinics of North America · 2023Review
- High-dimensional comparison of monocytes and T cells in post-COVID and idiopathic pulmonary fibrosis.Frontiers in immunology · 2023Article
- Predictors of pulmonary sequelae after COVID-19 pneumonia: A 12-month follow-up study.Frontiers in medicine · 2023Article
- Article
- Prognostic Factors for Pulmonary Fibrosis Following Pneumonia in Patients with COVID-19: A Prospective Study.Journal of clinical medicine · 2022Article
- Post-Coronavirus Disease 2019 Pulmonary Fibrosis: Wait or Needs Intervention.Tuberculosis and respiratory diseases · 2022Review
- Severe chronic cough relating to post-COVID-19 interstitial lung disease: a case report.Asia Pacific allergy · 2022Article
- Age-dependent virulence of human pathogens.PLoS pathogens · 2022Article
- Challenges in the Management of Post-COVID-19 Pulmonary Fibrosis for the Latin American Population.Journal of personalized medicine · 2022Article
- Multidimensional 3-Month Follow-Up of Severe COVID-19: Airways beyond the Parenchyma in Symptomatic Patients.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFew is known about the long-term pulmonary sequelae after COVID-19 infection. Hence, the aim of this study is to characterize patients with persisting pulmonary sequelae at follow-up after hospitalization. We also aimed to explore clinical and radiological predictors of pulmonary fibrosis following COVID-19.
methodsTwo hundred and 20 consecutive patients were evaluated at 3-6 months after discharge with high-resolution computed tomography (HRCT) and categorized as recovered (REC) or not recovered (NOT-REC). Both HRCTs at hospitalization (HRCT
resultsA total of 175/220 (80%) patients showed disease resolution at their initial radiological evaluation following discharge. NOT-REC patients (45/220; 20%) were mostly older men [66 (35-85) years vs. 56 (19-87);
conclusionsIn our population, only twenty percent of patients showed persistent lung abnormalities at 6 months after hospitalization for COVID-19 pneumonia. These patients are predominantly older men with longer hospital stay. The presence of reticulations and consolidation on HRCT at hospital admission predicts the persistence of radiological abnormalities during follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.